Aptose Biosciences Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Aptose Biosciences de 9.8% y 138.3% respectivamente, mientras que el BPA crecerá en un 37.4% al año.

Información clave

9.8%

Tasa de crecimiento de los beneficios

37.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.6%
Tasa de crecimiento de los ingresos	138.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	03 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents

Dec 08

Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data

Nov 12

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:APTO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	1	-40	N/A	-21	2
12/31/2024	N/A	-55	N/A	-55	3
12/31/2023	N/A	-51	-45	-45	N/A
9/30/2023	N/A	-49	-44	-44	N/A
6/30/2023	N/A	-48	-40	-40	N/A
3/31/2023	N/A	-44	-34	-34	N/A
12/31/2022	N/A	-42	-32	-32	N/A
9/30/2022	N/A	-56	-40	-40	N/A
6/30/2022	N/A	-58	-41	-41	N/A
3/31/2022	N/A	-61	-43	-43	N/A
12/31/2021	N/A	-65	-44	-43	N/A
9/30/2021	N/A	-56	-38	-38	N/A
6/30/2021	N/A	-58	-38	-38	N/A
3/31/2021	N/A	-60	-36	-36	N/A
12/31/2020	N/A	-55	-34	-34	N/A
9/30/2020	N/A	-48	-30	-30	N/A
6/30/2020	N/A	-42	-27	-27	N/A
3/31/2020	N/A	-32	-25	-25	N/A
12/31/2019	N/A	-26	-22	-22	N/A
9/30/2019	N/A	-25	-21	-21	N/A
6/30/2019	N/A	-24	-20	-20	N/A
3/31/2019	N/A	-28	-24	-24	N/A
12/31/2018	N/A	-29	-24	-23	N/A
9/30/2018	N/A	-26	-21	-21	N/A
6/30/2018	N/A	-23	-18	-18	N/A
3/31/2018	N/A	-15	-12	-12	N/A
12/31/2017	N/A	-12	-10	-10	N/A
9/30/2017	N/A	-11	N/A	-10	N/A
6/30/2017	N/A	-12	N/A	-11	N/A
3/31/2017	N/A	-14	N/A	-12	N/A
12/31/2016	N/A	-14	N/A	-12	N/A
9/30/2016	N/A	-15	N/A	-12	N/A
6/30/2016	N/A	-14	N/A	-12	N/A
3/31/2016	N/A	-12	N/A	-12	N/A
1/1/2016	N/A	-12	N/A	-10	N/A
9/30/2015	N/A	-9	N/A	-8	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
5/31/2014	N/A	-10	N/A	-8	N/A
2/28/2014	N/A	-7	N/A	-5	N/A
11/30/2013	N/A	-6	N/A	-4	N/A
8/31/2013	N/A	-5	N/A	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que APTO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que APTO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que APTO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que APTO no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que APTO no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de APTO se prevé que sea elevada dentro de 3 años.

Aptose Biosciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2025

Recent updates

Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024

Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024

Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC

Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.

New major risk - Shareholder dilution

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

New major risk - Share price stability

Independent Director recently bought US$53k worth of stock

Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib

New minor risk - Share price stability

Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.

Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Inc. Presents Highlights from Clinical Update

Aptose Biosciences Inc. announced that it expects to receive CAD 25 million in funding

Forecast to breakeven in 2025

Aptose Biosciences Inc. Updates Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

Aptose Biosciences Inc. Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Insufficient new directors

Aptose Biosciences Inc. to Report Q3, 2022 Results on Nov 01, 2022

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Biosciences Inc.’s New G3 Formulation of Luxeptinib Boosts Bioavailability

Aptose Biosciences Q2 2022 Earnings Preview

Aptose Biosciences Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department Regarding Minimum Bid Price Requirement

Aptose Biosciences Inc. to Report Q2, 2022 Results on Aug 02, 2022

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Aptose Appoints Fletcher Payne as Chief Financial Officer

Aptose Receives Fast Track Designation for Hm43239 in Relapsed/Refractory Aml Patients and Flt3 Mutation

Insufficient new directors

Aptose Biosciences Inc. to Report Q1, 2022 Results on May 09, 2022

Aptose Biosciences Inc. Announces Resignation of Dr. Jotin Marango as Chief Financial Officer

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

Aptose Biosciences Inc. Provides Update on APTO-253 Program

Independent Director recently bought US$316k worth of stock

Aptose Biosciences Inc. Announces HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

Insufficient new directors

Aptose: High Risk, High Reward. Watch Its Phase I Studies

Independent Director recently sold US$67k worth of stock

Aptose Biosciences (APTO) Presents Corporate Update at EHA 2021 - Slideshow

Aptose Presents Highlights from EHA2021 Virtual Congress During Corporate Update Event

Aptose Biosciences: An Assessment

Executive VP, Corporate Secretary, CFO & COO has left the company

Aptose Biosciences Inc. to Report Q4, 2020 Results on Mar 23, 2021

New 90-day low: US$3.98

Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents

New 90-day high: US$6.67

Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data

Aptose Biosciences Inc. to Present CG-806 and APTO-253 Data At the 2020 Ash Annual Meeting

Aptose Biosciences Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$4.75

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

New 90-day low - US$4.88

Aptose Biosciences Inc. to Report Q2, 2020 Results on Aug 04, 2020

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $55.125 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento